Krystal Biotech vs Protalix BioTherapeutics
KRYS and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRYS and PLX compare
Krystal Biotech is the larger company, worth 47 times as much as Protalix BioTherapeutics ($9.8B against $209M).
On earnings, Protalix BioTherapeutics is cheaper: it trades at 11.3× trailing earnings, against 41.6× for Krystal Biotech.
Protalix BioTherapeutics grew revenue faster over the last twelve months (30.1% versus 22.6% for Krystal Biotech).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with 23.5% at Protalix BioTherapeutics.
Protalix BioTherapeutics scores higher on the StockData Score (17 against 10 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRYS | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $9.8B | $209M |
| Share price | $332.29 | $2.59 |
| Change, 1 year | 79.6% | 9.3% |
| Change, 5 years | 548% | 133% |
| Beta (5Y) | 0.84 | 0.84 |
| Employees | 295 | 226 |
| StockData Score | ||
| Total score | 10 | 17 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 41.6× | 11.3× (better) |
| P/S | 22.3× | 2.6× (better) |
| P/B | 7.2× | 2.9× (better) |
| EV/EBITDA | 45.5× | 7.8× (better) |
| P/FCF | 38.2× | 27.2× (better) |
| FCF yield | 2.6% | 3.7% (better) |
| Fair value | $157.63 | $5.46 |
| Margin of safety | −111% | 52.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 22.6% | 30.1% (better) |
| Revenue growth, 5Y average | – | −3.5% |
| Net income growth (TTM) | 64.6% | 202% (better) |
| EPS growth (TTM) | 62.2% | 475% (better) |
| Profitability | ||
| Gross margin | – | 69.2% |
| Operating margin | 44.9% (better) | 28.9% |
| Net margin | 54.8% (better) | 23.5% |
| FCF margin | 58.5% (better) | 9.5% |
| Return on equity | 20.1% | 31.2% (better) |
| Return on invested capital | 45.3% | 49.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.32 (better) | 2.94 |
| Altman Z-score | 43.30 (better) | 5.30 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 17.9% |
| Held by insiders | 17.2% | 4.6% |
| Insider net buying, 12 months | −$105M | $101K (better) |
| Short interest, % of float | 14.2% | 4.0% |
Go deeper
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.